• 1. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 4. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

Recent Advances in the Application of 4-Bromo-2-ethoxy-1-(trifluoromethoxy)benzene (CAS: 1355247-61-8) in Chemical Biology and Pharmaceutical Research

The compound 4-Bromo-2-ethoxy-1-(trifluoromethoxy)benzene (CAS: 1355247-61-8) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential applications. This halogenated aromatic ether, characterized by the presence of bromo, ethoxy, and trifluoromethoxy substituents, serves as a versatile intermediate in the synthesis of bioactive molecules. Recent studies have explored its utility in drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents. The trifluoromethoxy group, known for its electron-withdrawing properties and metabolic stability, enhances the compound's pharmacological profile, making it a valuable scaffold for medicinal chemistry.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the use of 4-Bromo-2-ethoxy-1-(trifluoromethoxy)benzene as a key building block in the synthesis of novel Bruton's tyrosine kinase (BTK) inhibitors. The researchers employed palladium-catalyzed cross-coupling reactions to functionalize the bromo-substituted aromatic ring, yielding compounds with potent inhibitory activity against BTK, a target implicated in autoimmune diseases and B-cell malignancies. The incorporation of the trifluoromethoxy group was found to improve the compounds' pharmacokinetic properties, including plasma stability and membrane permeability.

In addition to its role in kinase inhibitor development, 4-Bromo-2-ethoxy-1-(trifluoromethoxy)benzene has been investigated as a precursor for antimicrobial agents. A recent Bioorganic & Medicinal Chemistry Letters article highlighted its use in the synthesis of fluoroquinolone derivatives with enhanced activity against drug-resistant bacterial strains. The ethoxy and trifluoromethoxy substituents were shown to modulate the compounds' binding affinity to bacterial DNA gyrase, while the bromo group served as a handle for further structural diversification.

The compound's utility extends beyond small-molecule drug discovery. A 2024 ACS Chemical Biology study reported its incorporation into proteolysis-targeting chimeras (PROTACs), bifunctional molecules designed to degrade disease-causing proteins. The researchers utilized 4-Bromo-2-ethoxy-1-(trifluoromethoxy)benzene as a linker between the target-binding moiety and the E3 ubiquitin ligase-recruiting moiety, taking advantage of its rigidity and synthetic accessibility. The resulting PROTACs demonstrated improved cellular uptake and target degradation efficiency compared to previous generations.

From a synthetic chemistry perspective, recent advances have focused on developing more efficient routes to 4-Bromo-2-ethoxy-1-(trifluoromethoxy)benzene. A 2023 Organic Process Research & Development paper described a scalable, one-pot procedure for its preparation from commercially available starting materials, employing continuous flow chemistry to enhance yield and purity. This methodological improvement addresses previous challenges associated with the large-scale production of this valuable intermediate.

Looking forward, the unique properties of 4-Bromo-2-ethoxy-1-(trifluoromethoxy)benzene position it as a promising scaffold for addressing current challenges in drug discovery, particularly in the development of targeted therapies and overcoming drug resistance. Ongoing research is exploring its application in covalent inhibitor design and as a component of antibody-drug conjugates. The compound's versatility, combined with recent synthetic advancements, suggests it will remain an important tool in medicinal chemistry for years to come.

• 1355246-82-0(4-bromo-2-butoxy-1-(trifluoromethoxy)benzene)
• 911116-31-9(Benzene, 4-bromo-1-methoxy-2-[3-(trifluoromethoxy)propoxy]-)
• 902757-20-4(Benzene, 4-bromo-1-(1-methylethoxy)-2-(trifluoromethoxy)-)
• 672948-65-1(4-Bromo-2-methoxy-1-(trifluoromethoxy)benzene)
• 2252-44-0(1-Bromo-3-(trifluoromethoxy)benzene)
• 352314-76-2(1-(Prop-2-ynyloxy)-2-(trifluoromethoxy)benzene)
• 690264-39-2(4-Bromo-2-(trifluoromethoxy)phenol)
• 853771-88-7(4-Bromo-2-(trifluoromethoxy)anisole)
• 1095544-42-5(5-Bromo-2-(difluoromethoxy)anisole)
• 1048963-39-8(5-Bromo-2-(trifluoromethoxy)phenol)